Item 1.
|
Security and Issuer
|
The Statement on Schedule 13D filed on August 24, 2018 (the Statement) by FCMI Parent Co. (FCMI Parent), FCMI Financial
Corporation (FCMI), Pan Atlantic Bank and Trust Limited, Friedberg Global-Macro Hedge Fund Ltd. (G-M Fund), Friedberg Mercantile Group, Ltd. (FMG) and
Albert D. Friedberg (collectively, the Filing Persons and each, individually, a Filing Person), relating to the common stock, par value $0.0001 per share (the Common Stock) of Vaccinex, Inc.,
a Delaware corporation (the Issuer), as amended by Amendment No. 1 to the
Statement filed July 31, 2019, Amendment
No. 2 to the Statement filed January 27, 2020, and Amendment No. 3 to the Statement filed July 16, 2020, is hereby further amended with respect to the matters set forth below in this Amendment. Capitalized terms not otherwise
defined herein have the meanings set forth in the Statement.
Preliminary Note: All Common Stock share amounts and percentage interests in this
Schedule 13D (Amendment No. 4) give effect to the 1-for-10 reverse stock split effected by the Issuer on August 7, 2018 in connection with the Issuers
initial public offering (IPO) completed on August 13, 2018.
Item 2.
|
Identity and Background
|
Item 2 of the Statement is hereby amended by the addition of the following information:
On October 1, 2021, Pan Atlantic Bank and Trust Limited voluntary gave up its Barbados Banking License and continues as a regular Barbados registered
business entity under its new name Pan Atlantic Holdings Ltd. (PAHL). Daniel G. Orezzoli Bozzalla, a citizen of Chile, joined as a director of PAHL. His principal occupation or employment includes Reprsentante Legal/Gerente General of
Toronto Trust as well as Director de empresa of Chisa (Chile South Apple). All other information related to Pan Atlantic Bank and Trust Limited set forth in the Statement, as amended, remains the same for PAHL.
During the last five years, none of the Filing Persons and to their knowledge, none of the directors or officers of FCMI Parent, FCMI, PAHL, G-M Fund or FMG
has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), nor was any of them a party to a civil proceeding of a United States judicial or administrative body of competent jurisdiction and as a result of
such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3.
|
Source and Amount of Funds or Other Consideration
|
Item 3 of the Statement is hereby amended by the addition of the following information:
The aggregate amount paid by FCMI Parent and G-M Fund for the shares of Common Stock it acquired pursuant to the Stock
Purchase Agreement referred to in Items 4 and 6 below and reported in Item 5 of this Amendment, was approximately $4,000,000.00. FCMI Parent and G-M Fund acquired the funds for such purchase from their working
capital.
Subsequent to July 16, 2020, a total of 2,148,034 shares of Common Stock issuable in exchange for certain partnership interests held by
FCMI Parent and FCMI were converted and are now held by FCMI Parent.
Item 4.
|
Purpose of Transaction.
|
Item 4 of the Statement is hereby amended by the addition of the following information:
FCMI Parent Co., G-M Fund and the Issuer entered into a Stock Purchase Agreement dated January 27, 2022, as
amended on January 31, 2022 (the Stock Purchase Agreement), pursuant to which, FCMI Parent Co. and G-M Fund each purchased 1,801,801 shares of Common Stock from the Issuer at a purchase price
of $1.11 per share, resulting in a total purchase price of $3,999,998.22. In the Stock Purchase Agreement, the Issuer states that it intends to use the net proceeds from the sale of the Common Stock to fund the ongoing development and clinical
trials of pepinemab, the adopted name for VX15, the Issuers lead product candidate, which is being developed for treatment of non-small cell lung cancer, osteosarcoma, melanoma and Huntingtons
disease. The Issuer will also use such proceeds for working capital and general corporate purposes. FCMI Parent and G-M Fund acquired the Common Stock reported herein for investment and to support the
Issuers research and development activities. For additional information regarding the Stock Purchase Agreement, see Item 6.
8